Sistema de Salut de Catalunya
Institut Català de la Salut
[Cedres S] Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Calvete J] Hospital Universitario Puerta del Mar, Cádiz, Spain. [Taylor Stokes G] Adelphi Real World, Adelphi Mill, Grimshaw Lane, Bollington, Macclesfeld, Cheshire, UK. [Álvarez Ayerza N, Vilanova Larena D] Bristol Myers Squibb, Madrid, Spain. [Daumont M] Bristol Myers Squibb, Braine L’Alleud, Belgium
Vall d'Hebron Barcelona Hospital Campus
2025-03-07T11:26:27Z
2025-03-07T11:26:27Z
2024
2025-01
Health-related quality of life; Malignant pleural mesothelioma; Treatment
Calidad de vida relacionada con la salud; Mesotelioma pleural maligno; Tratamiento
Qualitat de vida relacionada amb la salut; Mesotelioma pleural maligne; Tractament
Purpose Malignant pleural mesothelioma (MPM) is an aggressive cancer with long latency and poor prognosis. The real-world treatment patterns and humanistic burden of MPM in an international cohort of patients were recently published. Spanish data are currently lacking and are reported here. Methods/Patients Data were collected from three sources: physician-abstracted demographic, clinical and treatment characteristics of patients with MPM; patient-completed questionnaires on treatment satisfaction, symptoms, caregiver use, and impact of the disease; and caregiver-completed questionnaire reporting their activity and its impact on their daily life. Results The 241 patients in Spain were primarily elderly (median age: 67 years), male, retired/unemployed/on long-term sick leave, and diagnosed at stage IV with unresectable disease. Exposure to asbestos was detected (54%, 101/188). First-line treatment (1L) consisted primarily of doublet chemotherapy (86%, 207/241). Of 102 patients who completed 1L at data abstraction, 67 were receiving maintenance therapy, most commonly singlet chemotherapy with pemetrexed. Best supportive care was given to 29 patients, primarily after 1L (86.2%, 25/29). Symptom burden was high and health-related quality of life was poor and declined with progression: mean (SD) EQ-5D score and EQ-5D visual analogue scale score were 0.615 (0.285) and 60.8 (17.1) in 1L and 0.497 (0.370) and 56.1 (19.5) in second line. Overall, 67% of patients (162/241) required daily assistance from their caregiver, who reported an impact on their psychological well-being. Conclusions Patients with MPM in Spain were overall treated according to treatment guidelines at the time. Nevertheless, a considerable burden of disease was reported by patients and caregivers.
This study was funded by Bristol Myers Squibb.
Article
Published version
English
Qüestionaris; Pleura - Càncer - Tractament; Mesotelioma - Tractament; Pacients - Satisfacció; Assistència sanitària - Cost; DISEASES::Neoplasms::Neoplasms by Site::Thoracic Neoplasms::Respiratory Tract Neoplasms::Pleural Neoplasms; DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Glandular and Epithelial::Adenoma::Mesothelioma; Other subheadings::Other subheadings::Other subheadings::/drug therapy; HEALTH CARE::Environment and Public Health::Public Health::Epidemiologic Measurements::Demography::Health Status::Quality of Life; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Epidemiologic Methods::Data Collection::Surveys and Questionnaires; HEALTH CARE::Health Care Economics and Organizations::Economics::Costs and Cost Analysis::Cost of Illness; ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias torácicas::neoplasias del tracto respiratorio::neoplasias pleurales; ENFERMEDADES::neoplasias::neoplasias por tipo histológico::neoplasias glandulares y epiteliales::adenoma::mesotelioma; Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia; ATENCIÓN DE SALUD::ambiente y salud pública::salud pública::medidas epidemiológicas::demografía::estado de salud::calidad de vida; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::métodos epidemiológicos::recopilación de datos::encuestas y cuestionarios; ATENCIÓN DE SALUD::economía y organizaciones para la atención de la salud::economía::costes y análisis de costes::coste de las enfermedades
Springer
Clinical and Translational Oncology;27
https://doi.org/10.1007/s12094-024-03591-5
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
Articles científics - HVH [3439]
